[go: up one dir, main page]

PE20141050A1 - Inhibidores de quinasa relacionados con pirrolo (2,3-d) pirimidina tropomiosina - Google Patents

Inhibidores de quinasa relacionados con pirrolo (2,3-d) pirimidina tropomiosina

Info

Publication number
PE20141050A1
PE20141050A1 PE2013002178A PE2013002178A PE20141050A1 PE 20141050 A1 PE20141050 A1 PE 20141050A1 PE 2013002178 A PE2013002178 A PE 2013002178A PE 2013002178 A PE2013002178 A PE 2013002178A PE 20141050 A1 PE20141050 A1 PE 20141050A1
Authority
PE
Peru
Prior art keywords
pirrolo
tropomyosin
pyrimidine
kinase inhibitors
phenyl
Prior art date
Application number
PE2013002178A
Other languages
English (en)
Inventor
Mark David Andrews
Sharanjeet Kaur Bagal
Karl Richard Gibson
Kiyoyuki Omoto
Thomas Ryckmans
Sarah Elizabeth Skerratt
Paul Anthony Stupple
Original Assignee
Pfizer Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=45937493&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20141050(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pfizer Ltd filed Critical Pfizer Ltd
Publication of PE20141050A1 publication Critical patent/PE20141050A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

REFERIDO A COMPUESTOS DE FORMULA (I) DONDE: R1 ES H O ALQUILO C1-5 OPCIONALMENTE SUSTITUIDO CON HASTA 3 SUSTITUYENTES INDEPENDIENTEMENTE SELECCIONADOS DE OH, CH2OH, CN, NO2, ENTRE OTROS; R2 ES H O METILO; R3 ES H, ENTRE OTROS; R101 ES H, OH, METILO, CICLOPROPILO, METOXI, ETILO, ENTRE OTROS; R102 ES BENCIMIDAZOLILO, BENCISOXAZOLILO, BENZOFURANILO, BIFENILO, FENILO, ENTRE OTROS OPCIONALMENTE SUSTITUIDOS. UN COMPUESTO PREFERIDO ES: N-(5-{[2-AMINO-7-(2-HIDROXI-1,1-DIMETILETIL)-7H-PIRROLO[2,3-d]PIRIMIDIN-5-IL]CARBONIL}PIRIDIN-3-IL)-2-[4-(TRIFLUOROMETIL)FENIL]ACETAMIDA, ENTRE OTROS. REFERIDO A DEMAS A UNA COMPOSICION FARMACEUTICA. DICHOS COMPUESTOS SON ANTAGONISTAS DE Trk SIENDO UTILES PARA EL TRATAMIENTO DEL DOLOR
PE2013002178A 2011-04-05 2012-03-22 Inhibidores de quinasa relacionados con pirrolo (2,3-d) pirimidina tropomiosina PE20141050A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201161471758P 2011-04-05 2011-04-05

Publications (1)

Publication Number Publication Date
PE20141050A1 true PE20141050A1 (es) 2014-08-30

Family

ID=45937493

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2013002178A PE20141050A1 (es) 2011-04-05 2012-03-22 Inhibidores de quinasa relacionados con pirrolo (2,3-d) pirimidina tropomiosina

Country Status (32)

Country Link
US (2) US8846698B2 (es)
EP (1) EP2694509B1 (es)
JP (1) JP5595616B2 (es)
KR (1) KR20130133905A (es)
CN (1) CN103534257A (es)
AP (1) AP2013007159A0 (es)
AR (1) AR085852A1 (es)
AU (1) AU2012238369A1 (es)
BR (1) BR112013025792A2 (es)
CA (1) CA2832291C (es)
CL (1) CL2013002821A1 (es)
CO (1) CO6801740A2 (es)
CR (1) CR20130470A (es)
CU (1) CU20130129A7 (es)
DO (1) DOP2013000221A (es)
EA (1) EA201391239A1 (es)
EC (1) ECSP13013009A (es)
ES (1) ES2581848T3 (es)
GE (1) GEP20156417B (es)
GT (1) GT201300236A (es)
IL (1) IL228590A0 (es)
MA (1) MA35024B1 (es)
MX (1) MX2013011612A (es)
NI (1) NI201300103A (es)
PE (1) PE20141050A1 (es)
PH (1) PH12013502020A1 (es)
SG (1) SG193513A1 (es)
TN (1) TN2013000394A1 (es)
TW (1) TWI443101B (es)
UA (1) UA108926C2 (es)
UY (1) UY34004A (es)
WO (1) WO2012137089A1 (es)

Families Citing this family (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HK1208221A1 (en) * 2012-05-11 2016-02-26 Abbvie Inc. Nampt inhibitors
US20150218172A1 (en) 2012-10-04 2015-08-06 Pfizer Limited Pyrrolo[2,3-D]Pyrimidine Tropomyosin-Related Kinase Inhibitors
JP2015531395A (ja) 2012-10-04 2015-11-02 ファイザー・リミテッドＰｆｉｚｅｒ Ｌｉｍｉｔｅｄ ピロロ［３，２−ｃ］ピリジントロポミオシン関連キナーゼ阻害剤
EP2903986A1 (en) * 2012-10-04 2015-08-12 Pfizer Limited Tropomyosin-related kinase inhibitors
WO2014110574A1 (en) 2013-01-14 2014-07-17 Incyte Corporation Bicyclic aromatic carboxamide compounds useful as pim kinase inhibitors
ES2790419T3 (es) 2013-01-15 2020-10-27 Incyte Holdings Corp Los compuestos de tiazolcarboxamidas y piridinacarboxamida útiles como inhibidores de quinasa de PIM
WO2014149819A1 (en) 2013-03-14 2014-09-25 Kalyra Pharmaceuticals, Inc. Bicyclic analgesic compounds
JP2016169161A (ja) * 2013-07-19 2016-09-23 大日本住友製薬株式会社 新規イミダゾピリジン化合物
US9556197B2 (en) 2013-08-23 2017-01-31 Incyte Corporation Furo- and thieno-pyridine carboxamide compounds useful as pim kinase inhibitors
TWI731317B (zh) 2013-12-10 2021-06-21 美商健臻公司 原肌球蛋白相關之激酶（ｔｒｋ）抑制劑
CN108947867A (zh) 2013-12-12 2018-12-07 卡利拉制药公司 双环烷基化合物及合成
EP3083602A1 (en) 2013-12-20 2016-10-26 Pfizer Limited N-acylpiperidine ether tropomyosin-related kinase inhibitors
EP3097095A1 (en) * 2014-01-24 2016-11-30 AbbVie Inc. Furo-3-carboxamide derivatives and methods of use
CA2934043C (en) * 2014-02-05 2019-03-12 VM Oncology LLC Trka receptor tyrosine kinase antagonists and uses thereof
EP3114107B1 (en) 2014-03-07 2020-07-22 Recurium IP Holdings, LLC Propellane derivates and synthesis
WO2015143654A1 (en) * 2014-03-26 2015-10-01 Merck Sharp & Dohme Corp. TrkA KINASE INHIBITORS,COMPOSITIONS AND METHODS THEREOF
WO2015170218A1 (en) * 2014-05-07 2015-11-12 Pfizer Inc. Tropomyosin-related kinase inhibitors
CN103992319B (zh) * 2014-05-27 2015-09-16 天津市斯芬克司药物研发有限公司 一种吡啶羧酸类化合物的制备方法
US9580418B2 (en) 2014-07-14 2017-02-28 Incyte Corporation Bicyclic aromatic carboxamide compounds useful as Pim kinase inhibitors
WO2016010897A1 (en) 2014-07-14 2016-01-21 Incyte Corporation Bicyclic heteroaromatic carboxamide compounds useful as pim kinase inhibitors
WO2016009296A1 (en) 2014-07-16 2016-01-21 Pfizer Inc. N-acylpiperidine ether tropomyosin-related kinase inhibitors
WO2016020784A1 (en) 2014-08-05 2016-02-11 Pfizer Inc. N-acylpyrrolidine ether tropomyosin-related kinase inhibitors
EP3193855B1 (en) * 2014-09-17 2021-05-19 Recurium IP Holdings, LLC Bicyclic compounds
SG11201704872RA (en) 2014-12-18 2017-07-28 Genzyme Corp Pharmaceutical formulations of tropomyosin related kinase (trk) inhibitors
EP3239150B1 (en) 2014-12-24 2020-02-05 Takeda Pharmaceutical Company Limited Heterocyclic compound
CN105837574B (zh) * 2015-02-02 2018-03-02 四川大学 N‑(3‑哌啶基)‑芳香胺衍生物及其制备方法和用途
WO2016174664A1 (en) 2015-04-29 2016-11-03 Dexcel Pharma Technologies Ltd. Orally disintegrating compositions
US9540347B2 (en) 2015-05-29 2017-01-10 Incyte Corporation Pyridineamine compounds useful as Pim kinase inhibitors
WO2017027883A1 (en) 2015-08-13 2017-02-16 San Diego State University Research Foundation Atropisomerism for increased kinase inhibitor selectivity
AR105967A1 (es) 2015-09-09 2017-11-29 Incyte Corp Sales de un inhibidor de pim quinasa
KR102161364B1 (ko) 2015-09-14 2020-09-29 화이자 인코포레이티드 LRRK2 억제제로서 이미다조[4,5-c]퀴놀린 및 이미다조[4,5-c][1,5]나프티리딘 유도체
WO2017059251A1 (en) 2015-10-02 2017-04-06 Incyte Corporation Heterocyclic compounds useful as pim kinase inhibitors
US10076494B2 (en) 2016-06-16 2018-09-18 Dexcel Pharma Technologies Ltd. Stable orally disintegrating pharmaceutical compositions
EP3475280B1 (en) * 2016-06-23 2020-04-08 H. Hoffnabb-La Roche Ag Novel [1,2,3]triazolo[4,5-d]pyrimidine derivatives
CN107011347B (zh) * 2017-04-18 2019-01-18 华东师范大学 一种4-氯-7H-吡咯并[2,3-d]嘧啶的合成方法
EP3628043A4 (en) 2017-05-15 2021-04-28 Recurium IP Holdings, LLC ANALGESIC COMPOUNDS
ES2968421T3 (es) 2017-06-23 2024-05-09 San Diego State Univ Research Foundation Atropisomerismo para la selectividad potenciada de inhibidor de cinasa
TW201924683A (zh) 2017-12-08 2019-07-01 美商英塞特公司 用於治療骨髓增生性贅瘤的低劑量組合療法
TW202003519A (zh) * 2018-03-28 2020-01-16 日商武田藥品工業股份有限公司 雜環化合物及其用途
CN112839648B (zh) 2018-06-07 2025-04-04 达萨玛治疗公司 Sarm1抑制剂
CN109053575A (zh) * 2018-08-24 2018-12-21 遵义医学院 3-环丙基-1-甲基-1h-吡唑-4-甲醛的制备工艺
WO2020084389A1 (en) * 2018-10-23 2020-04-30 Lupin Limited Ribociclib intermediate and process for preparation thereof
JP7212781B2 (ja) 2018-12-19 2023-01-25 ディスアーム セラピューティクス， インコーポレイテッド 神経保護剤と組み合わせたｓａｒｍ１の阻害剤
KR102875569B1 (ko) 2018-12-20 2025-10-23 암젠 인크 Kif18a 억제제
CA3124569A1 (en) 2018-12-28 2020-07-02 Spv Therapeutics Inc. Cyclin-dependent kinase inhibitors
JP2022526713A (ja) 2019-03-21 2022-05-26 オンクセオ がんの処置のための、キナーゼ阻害剤と組み合わせたＤｂａｉｔ分子
JP2021050161A (ja) 2019-09-25 2021-04-01 武田薬品工業株式会社 複素環化合物及びその用途
JP2023500906A (ja) 2019-11-08 2023-01-11 インサーム（インスティテュ ナシオナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシェ メディカル） キナーゼ阻害剤に対する獲得抵抗性を有するがんの処置方法
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use
AR122141A1 (es) 2020-05-28 2022-08-17 Lilly Co Eli Inhibidor de trka
KR102889668B1 (ko) * 2020-11-03 2025-11-24 주식회사 엘지화학 작물보호제용 신규 화합물
EP4357347B1 (en) * 2021-06-21 2024-12-11 Henan Medinno Pharmaceutical Technology Co., Ltd. Trk kinase inhibitor compound and use thereof
CN121039104A (zh) 2023-04-06 2025-11-28 辉瑞大药厂 被取代的吲唑丙酸衍生化合物及其作为ampk活化剂的用途
WO2025007055A1 (en) * 2023-06-29 2025-01-02 Volastra Therapeutics, Inc. Aryl indol-3-yl ketone and aryl indazol-3-yl ketone inhibitors of kif18a
CN117720468A (zh) * 2023-12-15 2024-03-19 南开大学 一种用于筛选干预结直肠癌干细胞的靶点蛋白的活性探针
CN222533620U (zh) * 2024-05-11 2025-02-28 东莞市红象电子科技有限公司 按摩装置

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR0166088B1 (ko) 1990-01-23 1999-01-15 . 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
US5376645A (en) 1990-01-23 1994-12-27 University Of Kansas Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
GB9518953D0 (en) 1995-09-15 1995-11-15 Pfizer Ltd Pharmaceutical formulations
TW438796B (en) 1996-05-15 2001-06-07 Hoffmann La Roche 2,4-diaminopyrimidine derivatives, the manufacture process thereof, and the antibiotically-active pharmaceutical composition containing the same
WO2000035298A1 (en) 1996-11-27 2000-06-22 Wm. Wrigley Jr. Company Chewing gum containing medicament active agents
CA2283961A1 (en) * 1997-03-19 1998-09-24 Basf Aktiengesellschaft Pyrrolo[2,3d]pyrimidines and their use as tyrosine kinase inhibitors
GB9711643D0 (en) 1997-06-05 1997-07-30 Janssen Pharmaceutica Nv Glass thermoplastic systems
WO2001072751A1 (en) * 2000-03-29 2001-10-04 Knoll Gesellschaft Mit Beschraenkter Haftung Pyrrolopyrimidines as tyrosine kinase inhibitors
JP2003321472A (ja) 2002-02-26 2003-11-11 Takeda Chem Ind Ltd Ｇｒｋ阻害剤
GB0218168D0 (en) * 2002-08-06 2002-09-11 Astrazeneca Ab Compounds
UA80171C2 (en) 2002-12-19 2007-08-27 Pfizer Prod Inc Pyrrolopyrimidine derivatives
JP2007517868A (ja) 2004-01-07 2007-07-05 アストラゼネカ アクチボラグ 治療薬ｉ
US7417063B2 (en) 2004-04-13 2008-08-26 Bristol-Myers Squibb Company Bicyclic heterocycles useful as serine protease inhibitors
JP4842929B2 (ja) * 2004-05-27 2011-12-21 ファイザー・プロダクツ・インク 癌治療に有用なピロロピリミジン誘導体
US7846941B2 (en) * 2005-05-17 2010-12-07 Plexxikon, Inc. Compounds modulating c-kit and c-fms activity and uses therefor
EP1940822A1 (en) 2005-10-14 2008-07-09 NeuroSearch A/S Imidazole derivatives and their use for modulating the gaba-a receptor complex
GB0526044D0 (en) 2005-12-21 2006-02-01 Syngenta Ltd Novel herbicides
RU2323058C1 (ru) 2006-07-12 2008-04-27 ООО Научно-внедренческий центр "Машины и оборудование для энергетики" Способ формирования наружной резьбы на концевом участке трубной заготовки
DK2076508T3 (da) 2006-10-18 2011-02-21 Pfizer Prod Inc Biaryl-ether-urinstof-forbindelser
US7872018B2 (en) 2006-12-21 2011-01-18 Plexxikon, Inc. Compounds and methods for kinase modulation, and indications therefor
CL2008000835A1 (es) 2007-03-23 2008-10-03 Icagen Inc Pfizer Ltd Compuestos derivados de sulfonamidas, inhibidores de los canales de calcio; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento del dolor, sindrome de intestino irritable, enfermedad de crohn, taquiarritm
BRPI0810202A2 (pt) 2007-05-03 2014-10-21 Pfizer Ltd Derivados de piridina
EP2173743A2 (en) 2007-07-13 2010-04-14 Icagen, Inc. Sodium channel inhibitors
AU2008276063B2 (en) 2007-07-17 2013-11-28 Plexxikon Inc. Compounds and methods for kinase modulation, and indications therefor
WO2009143018A2 (en) * 2008-05-19 2009-11-26 Plexxikon, Inc. Compounds and methods for kinase modulation, and indications therefor
PE20091846A1 (es) 2008-05-19 2009-12-16 Plexxikon Inc DERIVADOS DE PIRROLO[2,3-d]-PIRIMIDINA COMO MODULADORES DE CINASAS
US8119637B2 (en) 2008-06-10 2012-02-21 Plexxikon Inc. Substituted pyrrolo[2,3-b]pyrazines and methods for kinase modulation, and indications therefor
WO2009152087A1 (en) 2008-06-10 2009-12-17 Plexxikon, Inc. Bicyclic heteroaryl compounds and methods for kinase modulation, and indications therefor
AU2010204118B2 (en) 2009-01-12 2012-12-20 Icagen, Inc. Sulfonamide derivatives
KR101483215B1 (ko) * 2010-01-29 2015-01-16 한미약품 주식회사 단백질 키나아제 저해활성을 갖는 비시클릭 헤테로아릴 유도체
TWI619713B (zh) 2010-04-21 2018-04-01 普雷辛肯公司 用於激酶調節的化合物和方法及其適應症

Also Published As

Publication number Publication date
TN2013000394A1 (fr) 2015-01-20
GEP20156417B (en) 2015-12-25
AU2012238369A1 (en) 2013-10-03
GT201300236A (es) 2015-08-04
NZ615557A (en) 2014-08-29
DOP2013000221A (es) 2014-03-16
EA201391239A1 (ru) 2014-03-31
MX2013011612A (es) 2013-10-17
JP5595616B2 (ja) 2014-09-24
TW201302757A (zh) 2013-01-16
WO2012137089A1 (en) 2012-10-11
CA2832291C (en) 2015-12-01
PH12013502020A1 (en) 2018-04-11
ES2581848T3 (es) 2016-09-07
EP2694509A1 (en) 2014-02-12
CR20130470A (es) 2013-10-16
US20140364415A1 (en) 2014-12-11
EP2694509B1 (en) 2016-05-18
SG193513A1 (en) 2013-10-30
CA2832291A1 (en) 2012-10-11
MA35024B1 (fr) 2014-04-03
AR085852A1 (es) 2013-10-30
BR112013025792A2 (pt) 2018-04-24
JP2014510131A (ja) 2014-04-24
CU20130129A7 (es) 2014-01-29
UA108926C2 (ru) 2015-06-25
US8846698B2 (en) 2014-09-30
NI201300103A (es) 2014-02-12
CO6801740A2 (es) 2013-11-29
CN103534257A (zh) 2014-01-22
IL228590A0 (en) 2013-12-31
CL2013002821A1 (es) 2014-02-21
ECSP13013009A (es) 2013-12-31
UY34004A (es) 2012-11-30
TWI443101B (zh) 2014-07-01
KR20130133905A (ko) 2013-12-09
US20120258950A1 (en) 2012-10-11
AP2013007159A0 (en) 2013-10-31

Similar Documents

Publication Publication Date Title
PE20141050A1 (es) Inhibidores de quinasa relacionados con pirrolo (2,3-d) pirimidina tropomiosina
PE20121509A1 (es) Compuestos de triazolopiridinas como inhibidores de quinasa mps-1
PE20081888A1 (es) ANALOGOS DE PIRAZOLOPIRIMIDINA Y SU USO COMO INHIBIDORES DE CINASA mTOR Y CINASA PI3
EA201201378A1 (ru) Определенные аминопиримидины, композиции на их основе и способы их использования
PE20140626A1 (es) Compuestos de bis(fluoroalquil)-1,4-benzodiazepinona
EA201201377A1 (ru) Определенные аминопиридазины, композиции на их основе и способы их использования
PE20141167A1 (es) Piridopirazinas sustituidas como inhibidores novedosos de ptk
PE20191613A1 (es) Compuestos de pirazolo[1,5-a]piridina sustituidos como inhibidores de la quinasa ret
ECSP14004812A (es) Triazolopiridinas sustituidas
EP4248988A3 (en) Alkenyl substituted 2,5-piperazinediones and their use in compositions for delivering an agent to a subject or cell
MX383688B (es) Derivados de piridona amida como agonistas de canales de sodio nav1. 8 y el uso de los mismos en el tratamiento de dolor.
EA200970207A1 (ru) Соединения пиридо[2,3-d]пиримидинона и их применение в качестве pi3 ингибиторов
MX2015011955A (es) Lipidos y composiciones de lipidos para el suministro de agentes activos.
PE20121335A1 (es) Compuestos derivados de amida como inhibidores de raf cinasas
PE20211782A1 (es) Compuestos de 5-cloro-2-difluorometoxifenil pirazolopirimidina, composiciones y metodos de uso de los mismos
PE20141380A1 (es) Imidazopiridazinas como inhibidores de quinasa akt
EA201390199A1 (ru) 2-замещенные-8-алкил-7-оксо-7,8-дигидропиридо[2,3-d]пиримидин-6-карбонитрилы и их применение
NZ629025A (en) Naphthyridine derivatives useful as alpha-v-beta-6 integrin antagonists
EA200900924A1 (ru) Циклизованные производные как ингибиторы eg-5
ECSP11011151A (es) Compuestos purina
AR062886A1 (es) Compuestos de tiazol pirazolopirimidina, composicion farmaceutica que lo comprende y su uso para preparar un medicamento
AR079497A1 (es) Derivados fenilimidazol que comprenden un enlazante de etinileno como inhibidores de enzima pde10a
PE20081159A1 (es) Inhibidores de las quinasas y metodos para su utilizacion
AR078278A1 (es) Antagonistas de la tiazol y oxazol hepcidina, composiciones farmaceuticas que los contienen y uso de los mismos para el tratamiento de anemias y enfermedades asociadas a deficiencias de hierro.
PE20141351A1 (es) Triazolopiridinas

Legal Events

Date Code Title Description
FD Application declared void or lapsed